Renato Quispe1, Abdulhamied Alfaddagh1, Brigitte Kazzi1, Fawzi Zghyer1, Francoise A Marvel1, Roger S Blumenthal1, Garima Sharma1, Seth S Martin2. 1. Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, 600 N. Wolfe St, Carnegie 591, Baltimore, MD, 21287, USA. 2. Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, 600 N. Wolfe St, Carnegie 591, Baltimore, MD, 21287, USA. smart100@jhmi.edu.
Abstract
PURPOSE OF REVIEW: We discuss current controversies in the clinical use of omega-3 fatty acids (FA), primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and examine discrepancies between recent trials. Furthermore, we discuss potential side effects reported in these studies and the role of mixed omega-3 FA dietary supplements and concerns about their use. RECENT FINDINGS: REDUCE-IT showed that addition of icosapent ethyl, a highly purified form of EPA, can reduce risk of cardiovascular events among statin-treated individuals with high triglycerides. Additional supportive evidence for EPA has come from other trials and meta-analyses of omega-3 FA therapy. In contrast, trials of mixed EPA/DHA products have consistently failed to improve cardiovascular outcomes. Discrepancies in results reported in RCTs could be explained by differences in omega-3 FA products, dosing, study populations, and study designs including the placebo control formulation. Evidence obtained from highly purified forms should not be extrapolated to other mixed formulations, including "over-the-counter" omega-3 supplements. Targeting TG-rich lipoproteins represents a new frontier for mitigating ASCVD risk. Clinical and basic research evidence suggests that the use of omega-3 FA, specifically EPA, appears to slow atherosclerosis by reducing triglyceride-rich lipoproteins and/or inflammation, therefore addressing residual risk of clinical ASCVD.
PURPOSE OF REVIEW: We discuss current controversies in the clinical use of omega-3 fatty acids (FA), primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and examine discrepancies between recent trials. Furthermore, we discuss potential side effects reported in these studies and the role of mixed omega-3 FA dietary supplements and concerns about their use. RECENT FINDINGS: REDUCE-IT showed that addition of icosapent ethyl, a highly purified form of EPA, can reduce risk of cardiovascular events among statin-treated individuals with high triglycerides. Additional supportive evidence for EPA has come from other trials and meta-analyses of omega-3 FA therapy. In contrast, trials of mixed EPA/DHA products have consistently failed to improve cardiovascular outcomes. Discrepancies in results reported in RCTs could be explained by differences in omega-3 FA products, dosing, study populations, and study designs including the placebo control formulation. Evidence obtained from highly purified forms should not be extrapolated to other mixed formulations, including "over-the-counter" omega-3 supplements. Targeting TG-rich lipoproteins represents a new frontier for mitigating ASCVD risk. Clinical and basic research evidence suggests that the use of omega-3 FA, specifically EPA, appears to slow atherosclerosis by reducing triglyceride-rich lipoproteins and/or inflammation, therefore addressing residual risk of clinical ASCVD.
Authors: Harold E Bays; Maurizio Averna; Claudio Majul; Dirk Muller-Wieland; Annamaria De Pellegrin; Hilde Giezek; Raymond Lee; Robert S Lowe; Philippe Brudi; Joseph Triscari; Michel Farnier Journal: Am J Cardiol Date: 2013-09-21 Impact factor: 2.778
Authors: R Preston Mason; Robert F Jacob; Sandeep Shrivastava; Samuel C R Sherratt; Amitabha Chattopadhyay Journal: Biochim Biophys Acta Date: 2016-10-05
Authors: Francine K Welty; Fabian Schulte; Abdulhamied Alfaddagh; Tarec K Elajami; Bruce R Bistrian; Markus Hardt Journal: FASEB J Date: 2021-04 Impact factor: 5.191
Authors: Richard L Dunbar; Stephen J Nicholls; Kevin C Maki; Eli M Roth; David G Orloff; Danielle Curcio; Judith Johnson; Douglas Kling; Michael H Davidson Journal: Lipids Health Dis Date: 2015-09-02 Impact factor: 3.876